Trial Profile

A Phase II Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab-rwlc (Libtayo) in Subjects With Recurrent or Progressive Glioblastoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; INXN 2001 (Primary) ; Veledimex (Primary)
Indications Glioblastoma
Focus Adverse reactions; Therapeutic Use
Sponsors Alaunos Therapeutics; ZIOPHARM Oncology

Most Recent Events

18 Apr 2025 Status changed from completed to discontinued.
03 Nov 2021 Status changed from active, no longer recruiting to completed.
19 Nov 2020 According to a ZIOPHARM Oncology media release, preliminary data from this study were presented Dr. Lukas at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com